Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Infections

Symptoms and General Pathology

Prostatic Neoplasms

Mycobacterium Infections

Communicable Diseases

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Bacterial Infections

Gram-Positive Bacterial Infections

Mycoses

Bacterial Infections and Mycoses

All Drugs and Chemicals

Antineoplastic Agents

Hormones

Docetaxel

Immunomodulating Agents

Adjuvants, Immunologic

Tubulin Modulators

Antimitotic Agents

Mycobacterium w.

Sudhir Rawal, MD

Arup Kumar Mandal, MD

Devakar Dalela, MD

N K Mohanty, M.D.

Jayesh Dhabalia, MD

Arun Chawla, MD

Sujata Patwardhan, MD

P G Jayaprakash, MD

Amil Lal Bhat, MD

Raju T Chacko, MD

Sushil Bhatia, MD

Kim Mammen, MD

K C Lakshmaiah, MD

Rajeev Gupta, MD

This study proposed the comparison the overall survival, hematological toxicity, pain reduction score,PSA levels, tumor response, quality of life in two arms of HRPC patients from different parts of India.

Prostate Cancer is a common health issue facing men worldwide in most of the patients cancer will shrink with hormonal therapy. In some cases cancer returns or continues to grow despite very low levels of circulating male hormones, which is called Androgen-Independent Prostate Cancer (AIPC) or Hormone Refractory Prostate Cancer (HRPC). Mycobacterium w is known to share multiple antigen including PSA. It administration is associated with antigen specific generation of cell mediated immunity. Docetaxel is found to useful in management of metastatic hormone refractory prostate cancer, which is associated with improved survival, tumor progression free survival with reduction in pain, serum PSA and improvement in quality of life. Cyclophosphamide 300mg/sq.m will be used to eliminate T-regulatory cell responsible immuno suppression. The vaccine Mycobacterium w will be administered on a day following cyclophosphamide. For better initiation of immune responses Docetaxel will be given seven days following first dose of Mycobacterium w.

A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer

Open Label, Randomized Multicentric Phase II Clinical Trial of Mycobacterium w in Combination With Docetaxel Versus Docetaxel in Metastatic Hormone Refractory Prostate Cancer.

Cadila Pharnmaceuticals

Carcinoma

Pomalidomide

Immunologic Factors

Angiogenesis Inhibitors

Growth Inhibitors

CC-4047

Phase II randomized open-label, two-arm study of safety and efficacy of CC-4047 in subjects with metastatic hormone refractory prostate cancer (HRPC)

Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)

Phase II Randomized Open-Label, Two-Arm Study of Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)

Celgene Corporation

Anti-Inflammatory Agents

Molgramostim

Sargramostim

Prednisone

Intermittent docetaxel/prednisone with no maintenance therapy: Patients will discontinue docetaxel/prednisone and undergo observation until disease progression at which time they will re-initiate docetaxel/prednisone. Six cycles of docetaxel/prednisone will again be administered before subsequent discontinuation of chemotherapy

Intermittent docetaxel/prednisone with maintenance GM-CSF therapy: Patients will discontinue docetaxel/prednisone and will receive maintenance GM-CSF until disease progression at which time, they will discontinue GM-CSF and resume docetaxel/prednisone. Six cycles of docetaxel/prednisone will again be administered before discontinuation of chemotherapy and GM-CSF therapy is re-initiated. GM-CSF dose/schedule will be as previously described (250 mcg/m2 SQ daily, days 15-28 q28 days)

Docetaxel 75mg/m2 every 21 days and GM-CSF 250mcg/m2 SQ days 15-28

Docetaxel and GM-CSF

Eric Small, MD

This is a two-arm, randomized Phase II study of intermittent chemotherapy with and without GM-CSF. All patients will receive six 21-day cycles of docetaxel 75 mg/m2 on Day 2 of each cycle and 5 mg prednisone twice a day on Days 1-21. Following six cycles of chemotherapy, eligible subjects will be randomized to no maintenance therapy or to maintenance GM-CSF therapy. The GM-CSF group dose schedule will be 250 mcg/m2 subcutaneous (SQ) daily Days 15-28 every 28 days. Patients in both groups will continue until disease progression at which time GM-CSF will be discontinued and chemotherapy will again be administered.

Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)

A Randomized Phase II Study of Intermittent Chemotherapy or Intermittent Chemotherapy With Maintenance GM-CSF in Patients With Previously Untreated Hormone Refractory Prostate Cancer

The Kaplan-Meier product limit method with 95% confidence intervals will be used to estimate the median time to disease progression during initial course of randomized treatment

The Kaplan-Meier product limit method will be used to estimate the median overall survival

PSA partial response is defined by at least a 50% decline from PSA value from the baseline measurement to 12 weeks of protocol therapy. The decline must be confirmed by a second PSA value obtained 4 or more weeks later For those patients whose PSA have decreased but has not reached response criteria defined above, progressive disease is defined as 25% increase over the nadir PSA value provided that the increase is at least 5ng/mL and is confirmed.

Median percentage of time will be calculated to summarize the total duration of chemotherapy and amount of docetaxel/prednisone administered while the patient is on study. The same results will be tabulated for each. For the on-chemotherapy period: will be estimated from the date of starting protocol therapy; if a patient received docetaxel on day 2 of a cycle, he will be considered to have received a full 21 days on therapy. For the off-chemotherapy period: will be calculated from the date of starting the observation or GM-CSF period to the date of resuming chemotherapy

Genzyme, a Sanofi Company

University of California, San Francisco

Data was not collected per intervention. All patients were assigned to the same treatment of Docetaxel/Prednisone before being assigned to the subsequent therapy arms where they may have received multiple treatment courses with multiple inductions. Abnormal lab values or test results constituted AEs only if they induced clinical signs /symptoms, required therapy, or required dose modification. There were no treatment-associated deaths.

All patients were assigned to received six 21-day cycles of docetaxel 75 mg/m2 on Day 2 of each cycle and 5 mg prednisone twice a day on Days 1-21. Following six cycles of chemotherapy, eligible subjects were randomized to no maintenance therapy or to maintenance GM-CSF therapy. Patients in both groups were followed until disease progression at which time GM-CSF was discontinued and another course of docetaxel and prednisone was administered again.

All Accrued Patients

There were a total of 125 patients whom were accrued to the study and assigned to at least one course of docetaxel

All Patients Accrued

Median Age Range

Age, Customized

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

United States

Region of Enrollment

8-10

The Gleason Score ranges from 1-8. Scores of 1-5 describe how much the cancer from a biopsy looks like healthy tissue (lower score) or abnormal tissue (higher score). Typical Gleason Scores range from 6-10. The higher the Gleason Score, the more likely that the cancer will grow and spread quickly. Since prostate tumors are often made up of cancerous cells with different grades, two grades are assigned for each patient. A primary grade for cells that make up the largest area of tumor and a secondary grade for cells of next largest area. Together they make up the total Gleason Score.

Gleason Score

* Induction Chemotherapy: Total number of patients enrolled, starting trial.
* Docetaxel/Docetaxel and GM-CSF: patients which passed 6 cycles of induction chemotherapy and had a ≥ 50 % PSA decline

Dr. Rahul Aggarwal

Docetaxel and Observation

* Docetaxel 75mg/m\^2 every 21 days
* GM-CSF 250mcg/m2 subcutaneous (SQ) days 15-28

Time to Progression

Docetaxel 75mg/m2 every 21 days GM-CSF 250mcg/m2 SQ days 15-28

Includes all patients whom received any treatment starting with first course of Docetaxel at Induction

Overall Survival

PSA response to Course 2 chemotherapy

PSA response to Course 3 chemotherapy

* Docetaxel 75mg/m2 every 21 days
* GM-CSF 250mcg/m2 SQ days 15-28

Twenty-six participants total resumed a second course of the Docetaxel, and five participants went on to resume a third course of treatment.

Number of Participants With PSA Response to Successive Series of Chemotherapy

Starting the docetaxel with observation period to date of resuming chemotherapy post initial induction

Docetaxel and Observation OFF Chemotherapy

Starting the docetaxel with GM-CSF period to date of resuming chemotherapy post initial induction

Docetaxel and GM-CSF OFF Chemotherapy

Starting Docetaxel 75mg/m2 and Observation every 21 days for at least 2 days

Docetaxel + Observation ON Chemotherapy

Starting Docetaxel 75mg/m2 and GM-CSF 250mcg/m2 SQ days 15-28 every 28 days with at least 2 days of Docetaxel

Docetaxel and GM-CSF ON Chemotherapy

Cumulative Duration of Time on and Off Docetaxel-based Therapy

Induction chemotherapy for 6 cycles (1 cycle = 21 days)

* Docetaxel 75mg/m\^2 I.V. (intravenous) on day 2
* Prednisone 5 mg by mouth (p.o.), twice a day (b.i.d.) from day 1 to 21 (for 21 days)

Pre-Randomization

Docetaxel 75mg/m\^2 every 21 days and GM-CSF 250mcg/m\^2 subcutaneously days 15-28

Induction Chemotherapy

Course 1

Course 2

Course 3

Response to Course 3

Epothilone B

Epothilones

Glucocorticoids

Hormone Antagonists

Antineoplastic Agents, Hormonal

Patupilone 8 mg/m2 + prednisone 5 mg bid daily

Patupilone 10 mg/m2 + prednisone days 1 -8 at 25 mg bid, day 9 at 20 mg bid, day 10 at 15 mg bid, day 11 at 10 mg bid, day 12 - 21 at 5 mg bid

Patupilone 10 mg/m2 + prednisone days 1 - 4 at 5 mg bid, days 5 -12 at 25 mg bid, day 13 at 20 mg bid, day 14 at 15 mg bid, day 15 at 10 mg bid, day 16 - 21 at 5 mg bid

Docetaxel 75 mg/m2 once every 3 weeks + prednisone 5 mg bid daily

Patupilone

prednisone

docetaxel

Novartis Pharmaceuticals

The objective of this study is to assess the response of patupilone plus prednisone compared to docetaxel plus prednisone on prostate specific antigen (PSA) in patients with metastatic hormone refractory prostate cancer. Additionally, this study will assess the response on measureable disease and the effects on patient-reported outcomes.

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

A Randomized Multicenter Phase II Trial of Patupilone (EPO906) Plus Prednisone Versus Docetaxel Plus Prednisone in Patients With Metastatic Hormone Refractory Prostate Cancer

Recurrence

Adenocarcinoma

Halichondrin B

Patients receive eribulin mesylate IV over 5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

eribulin mesylate

Mark Stein, M.D.

This phase II trial is studying how well eribulin mesylate (E7389; Halichondrin B Analog) works in treating patients with metastatic prostate cancer that did not respond to hormone therapy. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PRIMARY OBJECTIVES:

I. Determine the number of patients with a \> 50% decrease in prostate-specific antigen (PSA) of at least 4 weeks duration in patients with hormone-refractory metastatic prostate cancer treated with E7389 (eribulin mesylate).

SECONDARY OBJECTIVES:

I. Estimate the measurable disease response in patients with measurable disease.

II. Determine the duration of PSA and measurable disease response.

III. Characterize the safety and tolerability of E7389 in these patients.

OUTLINE:

This study enrolled 3 cohorts of patients based on the number of prior chemotherapy regimens received. The 3 cohorts are chemonaive stratum, prior-taxane stratum, and two-prior-chemotherapy stratum. Patients receive eribulin mesylate intravenously (IV) over 5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for 5 years.

Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

A Phase II Trial of E7389 (Halichondrin B Analog), in Patients With Metastatic Hormone Refractory Prostate Cancer

PSA response is defined as a PSA decline from baseline value by \>=50%, or normalization of PSA (\<0.2 ng/ml) confirmed by a second measurement greater than or equal to 4 weeks later.

Measurable disease response was evaluated using RECIST (Response Evaluation Criteria in Solid Tumors) 1.0 criteria. Per RECIST criteria, complete response (CR) = disappearance of all target and non-target lesions. Partial response (PR)= \>=30% decrease in the sum of the longest diameters of target lesions from baseline, and persistence of one or more non-target lesion(s) and/or the maintenance of tumor marker level above the normal limits. Measurable disease response = CR + PR. Only patients with measurable disease at baseline are included in this analysis.

National Cancer Institute (NCI)

All treated patients are evaluated for toxicities except for one patient who died soon after starting treatment and was not assessed for toxicity.

Eribulin Mesylate

Patients who did not receive any prior chemotherapy. Patients receive eribulin mesylate intravenously (IV) over 5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Chemonaive

Patients who received one prior taxane regimen. Patients receive eribulin mesylate intravenously (IV) over 5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Prior Taxane

Patients who received two prior chemotherapy regimens. Patients receive eribulin mesylate intravenously (IV) over 5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Two Prior Chemotherapy Regimens

Total

Age, Continuous

Eligible and treated patients are included in this analysis.

Study Statistician

Proportion of Patients With PSA Response

Eligible and treated patients with measurable disease at baseline are included in this analysis.

Proportion of Patients With Measurable Disease Response

Overall Study

Amino Acids

Dasatinib

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

Participants received dasatinib, 50 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 60 mg/m\^2.

Participants received dasatinib, 50 mg administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m\^2.

Participants received dasatinib, 70 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m\^2.

Participants received dasatinib, 100 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m\^2.

Participants received dasatinib, 120 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m\^2.

Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression

Infusion, 60 or 75 mg/m\^2, administered every 3 weeks.

Bristol-Myers Squibb

The purpose of this study is to find the recommended doses of dasatinib and docetaxel given in combination to men with metastatic hormone refractory prostate cancer and to assess the pharmacokinetic interactions between the 2 drugs.

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

Phase I/II Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

MTD was defined by dose-limiting toxicity (DLT) criteria. DLT was defined as grade 4 neutropenia causing treatment interruption for \>14 days, febrile neutropenia, grade 4 thrombocytopenia, grade 3 thrombocytopenia with a bleeding episode requiring platelet transfusion, nausea and/or vomiting despite medical intervention/prophylaxis causing treatment interruption for \>14 days, grade 3-4 asthenia/fatigue, any other grade \>=3 nonhematologic toxicity except alopecia or transient arthralgia/myalgia (unless unresponsive to intervention), or interruption of study drug for \>14 days due to toxicity. When defined, the MTD would serve as recommended Phase 2 dose of each drug in the combination of oral dasatinib and intravenous docetaxel.

Because no dose-limiting toxicities occurred, the recommended dose of dasatinib used in Phase 2 was based on findings from ongoing studies in chronic myelogenous leukemia and experience from the previous Phase 2 study of single-agent dasatinib in chronic refractory prostate cancer. The recommended Phase 2 dose of docetaxel (75 mg/m\^2) was based on the docetaxel package insert.

PSA response rate is defined as a decrease of \>=50% in PSA levels from baseline, sustained for at least 6 weeks and confirmed by at least 2 measurements

Duration of response is computed for participants with confirmed PSA response. It is measured in months from the time of the first of 2 consecutive measurements meeting the criteria for confirmed PSA response to the date of the first of 3 consecutive measurements that confirm PSA progression, the date of disease progression, or the date of death. Participants who neither progressed (PSA or disease) nor died were censored on the date of their last PSA assessment. PSA response is defined as a decrease of \>=50% in PSA levels from baseline, sustained for at least 6 weeks and confirmed by at least 2 measurements. PSA progression is defined as 3 consecutive increases in PSA from baseline or nadir, each measurement at least 1 week apart. The final confirming PSA measurement had to be ≥5ng/mL higher than baseline or nadir and also represent at least a 50% increase from baseline or nadir (ie, the value is ≥1.5\*baseline or nadir PSA).

PFS defined as time in months from the first dosing date to the date of disease progression or the date of death. Patients who neither progressed nor died were censored on the date of their last on-study prostate specific antigen (PSA) measurement, tumor assessment, or radionuclide bone scan assessment (whichever occurred last). Disease progression defined as either of the following: progression on radionuclide bone scan, death, or at least 2 of the following:

tumor progression, as defined by modified Response Evaluation Criteria in Solid Tumors; PSA progression; or investigator-defined clinical progression based on physical examination, history, symptoms, and performance status.

Objective response rate is defined as the percentage of participants who have achieved best responses of confirmed Complete Response (CR) or Partial Response (PR) where confirmed requires repeat evaluations for a minimum of 4 weeks after the criteria for response are first met. RECIST: CR=disappearance of clinical and radiologic evidence of target lesions; PR=a 30% or greater decrease in the sum of the longest diameter (LD) of all lesions in reference to the baseline sum LD.

RECIST for target lesions: Complete Response (CR)=disappearance of clinical and radiologic evidence of target lesions. Partial Response (PR)=a 30% or greater decrease in the sum of the longest diameter (LD) of all lesions in reference to the baseline sum LD. Stable disease (SD)=neither sufficient increase to qualify for Progressive Disease (PD) nor sufficient shrinkage to qualify for PR.

PD=a 20% or greater increase in the sum of LD of all target lesions, taking as reference the smallest sum LD recorded at or following baseline; unequivocal progression of nonmeasurable disease/lesions as evaluated by CT scan or MRI (not as evaluated by radionuclide bone scan) and/or new lesions are present.

To qualify as SD, patients had to exhibit SD for a minimum of 18 weeks. Those with evaluations noted as SD prior to 18 weeks and discontinued were reported as no change.

Stable=no new lesions appeared at any 6-week assessment or new pain was not developed in an area that was previously visualized for a minimum of 18 weeks; no change=stable disease prior to 18 weeks and then discontinued treatment; progression=2 or more new areas of focal uptake or new adverse clinical symptoms in an area previously visualized; improved=disappearance of at least 1 lesion, no new lesions appearing since the most recent prior assessment, and new pain not developing in an area that was previously visualized.

Improvement=disappearance of at least 1 lesion, no new lesions appearing since the most recent prior assessment, and new pain not developing in an area that was previously visualized

The BPI-sf assessed intensity of pain in the last 24 hours as well as impact of pain on daily functions. Patients rated the severity of their pain at its worst, least, and average in the last 24 hours using an 11-point rating scale with endpoints of no pain (0 points) and pain as bad as you can imagine (11 points). They were asked to rate their present pain and pain at the time they completed the BPI-sf. Using an 11-point rating scale with endpoints of does not interfere (0 points) and completely interferes (11 points), the BPI-sf similarly assessed to what extent pain interfered with mood, walking, general activity, work, relations with others, sleep, and enjoyment of life. The BPI-sf also asked patients to mark the location of their pain on a body drawing and included other questions about pain treatment and the extent of pain relief. The BPI-sf was collected in the Phase 2 portion of the study only. For on-treatment visits, the BPI-sf was completed prior to the docetaxel infusion.

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Drug-related=having certain, probable, possible, or missing relationship to study drug. Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Leading to death.

ULN=upper limit of normal. Graded by Common Toxicity Criteria: 1 (least severe) to 4 (life threatening ). Absolute neutrophil count (\*10\^9/L), Grade 3, \<1.0-0.5; Grade 4, \<0.5. Hemoglobin (mmol/L), Grade 3, \<4.9-4.0; Grade 4, \<4.0. Platelets (\*10\^9/L), Grade 3, \<50.0-25.0; Grade 4, \<25.0. Leukocytes (\*10\^9/L) Grade 3, \<2.0-1.0; Grade 4, \<1.0. ALP, ALT, and AST (\*ULN), Grade 3, \>5.0-20.0; Grade 4, \>20.0. Total bilirubin (\*ULN), Grade 3, \>3.0-10.0; Grade 4, \>10.0. Creatinine (\*ULN), Grade 3, \>3.0-6.0; Grade 4, \>6.0. Hypercalcemia (mmol/L), Grade 3, \>3.1-3.4; Grade 4, \>3.4. Hypocalcemia mmol/L), Grade 3, \<1.75-1.5; Grade 4, \<1.5. Hyperkalemia (mmol/L), Grade 3, \>6.0-7.0; Grade 4, \>7.0. Hypokalemia (mmol/L), Grade 3, \<3.0-2.5; Grade 4, \<2.5. Hypernatremia (mmol/L), Grade 3, \>155-160; Grade 4, \>160. Hyponatremia (mmol/L), Grade 3, \<130-120; Grade 4, \<120. Phosphorus (mmol/L), Grade 3, \<0.6-0.3; Grade 4, \<0.3. Prothrombin time (seconds), Grade 3, \>2.0; Grade 4, not defined.

Dasatinib, 100 mg + Docetaxel, 75 mg/m^2

Dasatinib, 120 mg + Docetaxel, 75 mg/m^2

Dasatinib, 50 mg + Docetaxel, 60 mg/m^2

Dasatinib, 50 mg + Docetaxel, 75 mg/m^2

Dasatinib, 70 mg + Docetaxel, 75 mg/m^2

Participants received dasatinib, 50 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 60 mg/m\^2. Provided no dose-limiting toxicities occurred, at least 3 participants received treatment in each arm.

Participants received dasatinib, 50 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m\^2. Provided no dose-limiting toxicities occurred, at least 3 participants received treatment in each arm.

All patients who received at least 1 dose of dasatinib

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer	NCT00525408	Hormone Refract...	Mycobacterium w... Docetaxel	18 Years -	Cadila Pharnmaceuticals
Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)	NCT00072722	Prostate Cancer	CC-4047	18 Years -	Celgene
Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)	NCT00488982	Prostate Cancer	Docetaxel Docetaxel and G...	18 Years -	University of California, San Francisco
Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer	NCT00411528	Metastatic Horm...	Patupilone prednisone docetaxel	18 Years -	Novartis
Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)	NCT00072722	Prostate Cancer	CC-4047	18 Years -	Celgene
Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy	NCT00337077	Adenocarcinoma ... Hormone-refract... Recurrent Prost... Stage IV Prosta...	eribulin mesyla...	18 Years -	National Cancer Institute (NCI)
Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer	NCT00411528	Metastatic Horm...	Patupilone prednisone docetaxel	18 Years -	Novartis
Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer	NCT00439270	Metastatic Pros...	Dasatinib Docetaxel	18 Years -	Bristol-Myers Squibb
Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer	NCT00439270	Metastatic Pros...	Dasatinib Docetaxel	18 Years -	Bristol-Myers Squibb
A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer	NCT00525408	Hormone Refract...	Mycobacterium w... Docetaxel	18 Years -	Cadila Pharnmaceuticals
Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)	NCT04477512	Metastatic Horm...	Cabozantinib Nivolumab Abiraterone ace... Prednisone Peripheral bloo...	18 Years -	Washington University School of Medicine

Spots Global Cancer Trial Database for metastatic hormone refractory prostate cancer